Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Primary effusion lymphoma (PEL) is a human herpes virus 8 (HHV8)-positive large B-cell neoplasm that presents as an effusion with no detectable tumor in individuals with human immunodeficiency virus infection or other immune deficiencies. PEL is an aggressive neoplasm with a poor prognosis. PEL cells show diverse morphologies, ranging from immunoblastic or plasmablastic to anaplastic. The immunophenotype of PEL is distinct, but its lineage can be misdiagnosed if not assessed thoroughly. PEL cells usually express CD45, lack B- and T-cell-associated antigens, and characteristically express lymphocyte activation antigens and plasma cell-associated antigens. Diagnosis of PEL often requires the demonstration of a B-cell genotype. HHV8 must be detected in cells to diagnose PEL. In most cases, PEL cells also harbor the Epstein-Barr virus (EBV) genome. Similar conditions associated with HHV8 but not effusion-based are called “extracavitary PELs.” PELs should be differentiated from HHV8-negative, EBV-positive, body cavity-based lymphomas in patients with long-standing chronic inflammation; the latter can occur in tuberculous pleuritis, artificial pneumothorax, chronic liver disease and various other conditions. Despite their morphological similarity, these various lymphomas require different therapeutic strategies and have different prognostic implications. Correct diagnosis is essential to manage and predict the outcome of patients with PEL and related disorders.
Abstract
Primary effusion lymphoma (PEL) is a human herpes virus 8 (HHV8)-positive large B-cell neoplasm that presents as an effusion with no detectable tumor in individuals with human immunodeficiency virus infection or other immune deficiencies. PEL is an aggressive neoplasm with a poor prognosis. PEL cells show diverse morphologies, ranging from immunoblastic or plasmablastic to anaplastic. The immunophenotype of PEL is distinct, but its lineage can be misdiagnosed if not assessed thoroughly. PEL cells usually express CD45, lack B- and T-cell-associated antigens, and characteristically express lymphocyte activation antigens and plasma cell-associated antigens. Diagnosis of PEL often requires the demonstration of a B-cell genotype. HHV8 must be detected in cells to diagnose PEL. In most cases, PEL cells also harbor the Epstein-Barr virus (EBV) genome. Similar conditions associated with HHV8 but not effusion-based are called “extracavitary PELs.” PELs should be differentiated from HHV8-negative, EBV-positive, body cavity-based lymphomas in patients with long-standing chronic inflammation; the latter can occur in tuberculous pleuritis, artificial pneumothorax, chronic liver disease and various other conditions. Despite their morphological similarity, these various lymphomas require different therapeutic strategies and have different prognostic implications. Correct diagnosis is essential to manage and predict the outcome of patients with PEL and related disorders.
참고문헌 (48)
- Said J, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.260~261 (2008), IARC Press
- Said J, "Hematopathology", pp.867~883 (2011), Elsevier Saunders
- Cesarman E, "Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas", N Engl J Med, 332, pp.1186~1191 (1995)
- Chadburn A, "KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma", Am J Surg Pathol, 28, pp.1401~1416 (2004)
- Cesarman E, "Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients", Cancer Lett, 305, pp.163~174 (2011)
- Petitjean B, "Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype", Am J Surg Pathol, 26, pp.724~732 (2002)
- Ohsawa M, "Role of Epstein-Barr virus in pleural lymphomagenesis", Mod Pathol, 8, pp.848~853 (1995)
- Ichinohasama R, "Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature", Am J Surg Pathol, 22, pp.1528~1537 (1998)
- Alexanian S, "KSHV", HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states, 2013, pp.37, 241~249
- 하상윤, "Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation Manifested as a Soft Tissue Mass: Incidental Discovery on Histological Examination", Journal of Pathology and Translational Medicine, 45(4), pp.417~422 (2011), 대한병리학회
- Yoon SO, "Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5,318 cases according to the World Health Organization classification", Am J Hematol, 85, pp.760~764 (2010)
- 김진만, "WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study", Journal of Pathology and Translational Medicine, 45(3), pp.254~260 (2011), 대한병리학회
- Ariza-Heredia EJ, "Human herpes virus 8 in solid organ transplantation", Transplantation, 92, pp.837~844 (2011)
- Moore PS, "Molecular virology of Kaposi’s sarcoma-associated herpesvirus", Philos Trans R Soc Lond B Biol Sci, 356, pp.499~516 (2001)
- de Sanjose S, "Geographic variation in the prevalence of Kaposi sarcoma-associated herpesvirus and risk factors for transmission", J Infect Dis, 199, pp.1449~1456 (2009)
- Han TH, "Seroprevalence of human herpesvirus 8 in children in Seoul, Korea", Pediatr Infect Dis J, 24, pp.476~ (2005)
- Lennette ET, "Antibodies to human herpesvirus type 8 in the general population and in Kaposi’s sarcoma patients", Lancet, 348, pp.858~861 (1996)
- Jenkins FJ, "Reactivation of and primary infection with human herpesvirus 8 among solid-organ transplant recipients", J Infect Dis, 185, pp.1238~1243 (2002)
- Edelman DC, "Human herpesvirus 8: a novel human pathogen", Virol J, 2, pp.78~ (2005)
- Ganem D, "KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine", J Clin Invest, 120, pp.939~949 (2010)
- Gantt S, "Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment", Curr Opin Infect Dis, 24, pp.295~301 (2011)
- Carbone A, "AIDS-related lymphomas: from pathogenesis to pathology", Br J Haematol, 130, pp.662~670 (2005)
- Nador RG, "Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus", Blood, 88, pp.645~656 (1996)
- Ansari MQ, "Primary body cavity-based AIDS-related lymphomas", Am J Clin Pathol, 105, pp.221~229 (1996)
- Deloose ST, "High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic", plasmablastic diffuse large B-cell lymphoma, 2005, pp.19, 851~855
- Pan ZG, "Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases", Am J Surg Pathol, 36, pp.1129~1140 (2012)
- Patel S, "Primary effusion lymphoma", Arch Pathol Lab Med, 137, pp.1152~1154 (2013)
- Carbone A, "Expression profile of MUM1", IRF4, BCL-6, and CD138, Blood, pp.2001, 97[DOI]
- Vega F, "Diagnostic pathology: lymph nodes and spleen with extranodal lymphomas", pp.7~85 (2011), Amirsys
- Coupland SE, "HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man", Am J Surg Pathol, 29, pp.647~652 (2005)
- Klein U, "Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts", Blood, 101, pp.4115~4121 (2003)
- Ferry JA, "Extramodal lymphomas", pp.81~132 (2011), Saunders-Elsevier
- 강소영, "원발성삼출액림프종 3례", Blood Research, 38(2), pp.8~141 (2003), 대한혈액학회
- Kim YA, "Primary effusion lymphoma and human herpesvirus 8-negative effusion-based lymphoma: analysis of 17 cases in Korea", Korean J Pathol, 47(Suppl 1), pp.S100~ (2013)
- Chan JK, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.245~246 (2008), IARC Press
- Stein H, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.256~257 (2008), IARC Press
- 이향임, "HIV 음성 환자에서 형질모세포종의 세침흡인 세포소견 -1예 보고-", 대한세포병리학회지, 16(1), pp.47~51 (2005), 대한세포병리학회
- Delsol G, "WHO cclassification of tumours of haematopoietic and lymphoid tissues", pp.312~316 (2008), IARC Press
- McKenna RW, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.200~213 (2008), IARC Press
- Vega F, "Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles", Mod Pathol, 18, pp.806~815 (2005)
- Kim Y, "Extracavitary", solid variant of primary effusion lymphoma, 2012, pp.16, 441~446
- Delsol G, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.254~255 (2008), IARC Press
- Isaacson PG, "WHO classification of tumours of haematopoietic and lymphoid tissues", pp.258~259 (2008), IARC Press
- Ohori NP, "Primary pleural effusion posttransplant lymphoproliferative disorder: Distinction from secondary involvement and effusion lymphoma", Diagn Cytopathol, 25, pp.50~53 (2001)
- Lechapt-Zalcman E, "Posttransplantation lymphoproliferative disorder mimicking a nonspecific lymphocytic pleural effusion in a bone marrow transplant recipient. A case report", Acta Cytol, 43, pp.239~242 (1999)
- Ripamonti D, "Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection", AIDS, 22, pp.1236~1237 (2008)
- Siddiqi T, "A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab", Clin Lymphoma Myeloma, 8, pp.300~304 (2008)
- Ghosh SK, "Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B", Blood, 101, pp.2321~2327 (2003)